High Efficiency T-Cell Editing- Utilizing CRISPRevolution™ Synthetic sgRNA

Are you looking for a way to efficiently edit and sustain cell viability for immunotherapies? Using Synthego’s modified synthetic sgRNA, you can achieve efficient, multigene knockout in primary human resting CD4+ T-Cells.

Chimeric Antigen Receptor and T Cell Receptor immunotherapies use incredibly valuable and scarce cells from donated human tissue to treatment for various blood cancers and explore new cancer therapeutics. Modified synthetic sgRNA can help can help address the challenges in creating these therapies. Explore this demonstrations of gene knockout in human primary T cells using Synthego’s modified synthetic sgRNA following CRISPR/Cas9 RNP nucleofection.